Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electroconvulsive Treatment for Depression Alters Mitochondrial Serum Metabolites.

Biological psychiatry global open science·2026
Same author

Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers: A Disordinal Effect.

Biological psychiatry·2026
Same author

MCMC Correction of Score-Based Diffusion Models for Model Composition.

Entropy (Basel, Switzerland)·2026
Same author

Ancestral FUT2 genetic adaptation confers resistance to modern norovirus and rotavirus infections.

Current opinion in virology·2026
Same author

Exploring faculty self-assessment on Clinician Educator Milestones: insights from a multi-institutional study.

Academic medicine : journal of the Association of American Medical Colleges·2026
Same author

Cognitive and occupational functioning in bipolar disorder and ADHD: impact of comorbidity.

The British journal of psychiatry : the journal of mental science·2026

Related Experiment Video

Updated: Jun 21, 2026

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

Increased cortical nitric oxide release after phencyclidine administration.

Erik Pålsson1, Niall Finnerty, Kim Fejgin

  • 1Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden. erik.palsson@pharm.gu.se

Synapse (New York, N.Y.)
|July 31, 2009
PubMed
Summary

Phencyclidine increases nitric oxide (NO) in rat brains, mimicking schizophrenia models. Inhibiting nitric oxide synthase with L-NAME normalized these NO levels, suggesting NO

More Related Videos

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

Assessment of Social Interaction Behaviors
06:41

Assessment of Social Interaction Behaviors

Published on: February 25, 2011

Related Experiment Videos

Last Updated: Jun 21, 2026

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

Assessment of Social Interaction Behaviors
06:41

Assessment of Social Interaction Behaviors

Published on: February 25, 2011

Area of Science:

  • Neuroscience
  • Psychopharmacology
  • Biochemistry

Background:

  • Phencyclidine (PCP) induces psychotomimetic effects and cognitive deficits in rats, serving as a model for schizophrenia.
  • These PCP-induced cognitive deficits are reversible by inhibiting nitric oxide synthase (NOS).
  • Nitric oxide (NO) is implicated in various brain functions, and its role in PCP's effects requires direct investigation.

Purpose of the Study:

  • To investigate the effect of phencyclidine (PCP) on nitric oxide (NO) levels in the medial prefrontal cortex of rats.
  • To examine whether L-NAME, a nitric oxide synthase inhibitor, can modulate PCP-induced changes in NO levels.
  • To utilize long-term in vivo electrochemistry (LIVE) for real-time NO measurements in freely moving rats.

Main Methods:

  • Employed long-term in vivo electrochemistry (LIVE) to measure nitric oxide (NO) levels in the medial prefrontal cortex.
  • Administered phencyclidine (PCP) at 2 mg/kg to rats.
  • Co-administered PCP with L-NAME (10 mg/kg), a nitric oxide synthase inhibitor.

Main Results:

  • Phencyclidine (PCP) administration resulted in a significant increase in cortical nitric oxide (NO) levels.
  • The PCP-induced elevation of NO levels was attenuated by the co-administration of L-NAME.
  • LIVE technology provided direct biochemical evidence of NO modulation in the medial prefrontal cortex.

Conclusions:

  • The study provides biochemical evidence supporting the involvement of nitric oxide (NO) in the phencyclidine (PCP) model of schizophrenia.
  • Inhibition of nitric oxide synthase (NOS) effectively counteracted PCP-induced NO increases in the medial prefrontal cortex.
  • These findings strengthen the rationale for targeting the nitric oxide pathway in schizophrenia research.